Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma

15 Nov 2018

Abstract excerpt

Synovial sarcoma tumours contain a characteristic fusion protein, SS18-SSX, which drives disease development. Targeting oncogenic fusion proteins presents an attractive therapeutic opportunity. However, SS18-SSX has proven intractable for therapeutic intervention. Using a domain-focused CRISPR screen we identified the bromodomain of BRD9 as a critical functional dependency in synovial sarcoma. BRD9 is a component...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30431433
DOI: 10.7554/elife.41305

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcomaPMID 30431433Read ↗

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial SarcomaSemantic proximity Read ↗

Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial SarcomaSemantic proximity Read ↗

SUMO2 Inhibition Reverses Aberrant Epigenetic Rewiring Driven by Synovial Sarcoma Fusion Oncoproteins and Impairs SarcomagenesisSemantic proximity Read ↗

Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial SarcomaSemantic proximity Read ↗

Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcomaSemantic proximity Read ↗

DNA demethylating agents suppress preclinical models of synovial sarcomaSemantic proximity Read ↗

ATR Is a Therapeutic Target in Synovial SarcomaSemantic proximity Read ↗

Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stabilitySemantic proximity Read ↗

A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18–SSX Induces Canonical BAF DestructionSemantic proximity Read ↗

Molecular Profiling Defines Three Subtypes of Synovial SarcomaSemantic proximity Read ↗

Therapeutic Potential of Bromodomain and Extra-Terminal Domain Inhibitors for Synovial Sarcoma CellsSemantic proximity Read ↗

Histone Deacetylase Inhibitors Reverse SS18-SSX–Mediated Polycomb Silencing of the Tumor Suppressor <i>Early Growth Response 1</i> in Synovial SarcomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.